China Medical Device Webinar with AdvaMed Accel for U.S. exporters
11:00 AM to 12:10 PM
(GMT-05:00) Eastern Time (US and Canada)


Are you looking to expand your medical device-related sales to a new global market? Join us at the “China Medical Device Webinar with AdvaMed Accel for U.S. Exporters” where you’ll find the experts, answers, and resources small companies need to identify new markets in China's dynamic medical device sector. The webinar will cover market opportunities, reimbursement, market access requirements, IP considerations, and regulatory updates for small and medium-sized manufacturers.

The medical device market in China will expand by a 2022-2027 CAGR of 9.1% in US dollar terms, which should see it rise to USD 49.5 bn by 2027. The U.S. supplied imports valued at USD 5.6 bn in 2021, equal to 27.2%. China’s medical device market offers opportunities for imported innovative products across a range of market segments that are experiencing sustained demand.  Learn how you can take advantage and register today! (Please click the registration button, and sign in with your existing InEvent account or create a new account for registration. If you have any questions, please contact 

Date and Time: 11:00 am, October 18, EST/8:00 am, October 18, Pacific Time

  • Welcome Remarks, Everett Wakai, Minister Counselor for Commercial Affairs, U.S. Embassy Beijing (5 minutes)
  • China Medical Device Market Overview, Chang ZHANG, Senior Principal, IQVIA (15 minutes)
  • NMPA Regulatory Requirements and Registration Pathway, Hamish King, Chief Executive Officer, Cisema (15 minutes)
  • IP Protection in China, Conrad Wong, IP Attaché, U.S. Patent and Trademark Office China (20 minutes)
  • Q&A (10 minutes)
11:00-11:05           Welcome Remarks, Everett Wakai, Minister Counselor for Commercial Affairs, U.S. Embassy Beijing
11:05-11:20            China Medical Device Market Overview, Chang ZHANG, Senior Principal, IQVIA
11:20-11:35            NMPA Regulatory Requirements and Registration Pathway, Hamish King, Chief Executive Officer,  Cisema 
11:35-11:55            IP Protection in China, IP Attaché, U.S. Patent and Trademark Office
11:55-12:05         Q&A
11:00 AM
12:10 PM

Everett Wakai

Minster Counselor for Commercial Affairs, U.S. Embassy Beijing

Everett Wakai currently serves as the Minister Counselor for Commercial Affairs at the U.S. Embassy, Beijing. He leads a binational team of American commercial diplomats and Chinese trade experts to promote U.S. - China business development, trade and investment. Before moving to Beijing, Mr. Wakai was the Commercial Counselor at the U.S. Consulate, Shanghai.
Mr. Wakai previously served as the Senior Commercial Officer at the U.S. Embassy, in Angola, where his worked focused on improving the business climate, diversifying the economy and trade and foreign exchange payments. As an ex-officio Board Member of the newly formed AmCham Angola he led efforts to stand up a corporate compliance program, form policy committees and formulate AmCham Angola’s strategy and positioning.
Previously, he was assigned to the U.S. Commercial Service New Orleans Office where he assisted U.S. companies develop and implement their export promotion strategies. Prior to joining the New Orleans office, he was the Standards Attaché for South America responsible for standards and trade cooperation, market access and market development at the U.S. Consulate General in Sao Paulo, Brazil. He also served as the Standards Attaché for Mexico, Canada, and Central America responsible for NAFTA rule of origin exports, standards and regulatory cooperation in the healthcare and the energy sectors at the American Embassy in Mexico. He began his career with the U.S. Commercial Service as the Energy and Cleantech Commercial Advisor at the U.S. Embassy, Paris, France.
Mr. Wakai is a graduate of the University of California at Santa Barbara, holds a master’s degree from New York University and received his MBA from Krannert Business School at Purdue University.

Conrad W. Wong

Senior Attorney, U.S. Patent and Trademark Office (PTO)

Conrad Wong is a Senior Attorney with the China Team in the Office of Policy and International Affairs at the headquarters of the Patent and Trademark Office (PTO) in Alexandria, Virginia.  He specializes in American and Chinese intellectual property law and enforcement matters, formulates and promotes U.S. intellectual property policy, and assists rights holders in registering and protecting their intellectual property assets.

From 2007 to 2012 and again from 2019 to 2022, he was resident in China, representing the PTO as the Intellectual Property Officer with the United States Consulate General in Guangzhou.  Concurrent with his assignment to the China Team at PTO Alexandria, he continues to supervise remotely the activities and local staff of PTO Guangzhou.  He is responsible for American intellectual property issues in southern and southwestern China as well as the Special Administrative Regions of Hong Kong and Macao.

He has 30 years of experience in intellectual property matters, representing the United States Government and the private sector.  In 1993, he joined the PTO as a Trademark Examiner, became a Senior Attorney, and then joined the Office of Policy and International Affairs.  Prior experience includes clerking for a Maryland state trial judge, and litigation practice in insurance-defense matters in Washington, D.C.  He has served as a government-relations representative for an automotive trade association.

He is a graduate of The Johns Hopkins University and Georgetown University Law Center.  Fluent in Cantonese, he is admitted to practice law in the District of Columbia and the State of Maryland.


Senior Principal, IQVIA

Chang heads IQVIA China's MedTech Consulting practices. He has 15 years of experience as a strategy consultant. He has been working in healthcare covering pharmaceuticals, MedTech, and healthcare services
He advises on diversified topics incl. strategy, portfolio, market access, product launch and pricing, patient management, etc. He also advises commercial, clinical, and technical investment/divest decisions for industry and financial investors.
Chang holds a B.S. in Clinical Pharmacology from Wuhan University, Master in Biochemistry from the University of Paris XI and Institut Pasteur Paris and a Master in Management from HEC Paris, Grande Ecole.

Hamish King

Chief Executive Officer, Cisema

Hamish King is Chief Executive Officer at Cisema, a regulatory consultancy and CRO for China founded in Munich and Beijing in 2002. A lawyer by training - admitted in Hong Kong and NSW, Australia - Hamish supports medical device & IVD companies experience smooth and efficient China registrations. Formerly with UK Magic Circle Firm Linklaters in Hong Kong, he has nearly 10 years' experience in the legal and regulatory fields and has obtained the RAC and CFA qualifications.